Getein Biotech(SH:603387)2022-04-29 09:47Financial Performance - In 2021, the company's POCT segment achieved revenue of 0.923 billion CNY, a 62% increase year-on-year [2] - The overall revenue growth reached 76%, with the immunology segment generating sales of 95.86 million CNY [2] - The hemostasis segment reported revenue of 40.24 million CNY, reflecting a 107% year-on-year growth [2] Market Strategy and Challenges - The company views centralized procurement as both a challenge and an opportunity, aiming to enhance market share and drive growth [3] - The company plans to leverage experiences from Anhui's centralized procurement to adapt to various forms of procurement reforms nationwide [3] Product Development and Feedback - The small luminescence product, Magicl6000, has received positive market feedback due to its compact size and high automation [3] - The company plans to launch a small automated production line by Q4 2022, integrating multiple instruments for combined testing [3][4] Future Plans and Innovations - The Getein1600 has been installed in over 6,000 units, with annual installations exceeding 1,000 [3] - The company is set to introduce the BHA-5100 fully automated blood cell analyzer and a new small production line in the second half of 2022 [4] - The development of the Getein3200 biochemical immunoassay analyzer aims to provide rapid results, with a target of 3 minutes for dry biochemical projects [4] Strategic Focus - The company emphasizes the importance of conventional product development for sustained performance growth, expanding into IVD across various fields [4] - There is a strategic shift towards high-end hospitals, with a focus on automation and quality control improvements [4]